Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614470 | 0.81 | TSHR (0.50) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL193239 | 0.79 | TSHR (0.48) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL6488904 | 0.79 | TSHR (0.48) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL1527604 | 0.79 | TSHR (0.48) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL22034596 | 0.77 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL1585013 | 0.77 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| Bromide SCHEMBL31119163 | 0.77 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL13779263 | 0.76 | TSHR (0.40) | TSHRTP53TDP1POLBALDH1A1 | |
| SCHEMBL22034670 | 0.75 | TSHR (0.43) | TSHRTP53TDP1POLBALDH1A1 | |
| SCHEMBL1071833 | 0.75 | TSHR (0.43) | TSHRTP53TDP1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852239-A | Method for preparing perfluorophosphonate vinyl ether monomer from perfluorovinyl ether halide in one step | 山东东岳未来氢能材料股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119613397-A | N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors | 迈巴制药(南京)有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250042853-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-115785014-B | Tetrazole derivatives and uses thereof | 瑞石生物医药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118852239-A | Method for preparing perfluorophosphonate vinyl ether monomer from perfluorovinyl ether halide in one step | 山东东岳未来氢能材料股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4428125-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-118525022-A | Azacyclo derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-118388466-A | Amide derivatives as sodium channel modulators and uses thereof | 安润医药科技（苏州）有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118139865-A | Pyrrolopyrazoles | 正大天晴药业集团股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-114507202-B | Phellinin compound and preparation method and application thereof | 海南大学 | 2023-10-03 | — | — | CN | disclosed |
| CN-116693519-A | Compound containing five-membered heteroaromatic ring structure, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116375701-A | Bicyclic heterocyclic compounds, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023078369-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023274383-A1 | KRAS G12D INHIBITOR AND USE THEREOF | 上海迪诺医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-114573438-A | Mono-fluorine chlorine/bromoacetone compound and preparation method thereof | 上海应用技术大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-113278022-A | Pyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof | 南京纳丁菲医药科技有限公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-110023286-B | Biphenyl compounds as CCR2/CCR5 receptor antagonists | 南京明德新药研发有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
| WO-2020224626-A1 | COMPOUND USED AS KINASE INHIBITOR AND APPLICATION THEREOF | 浙江同源康医药股份有限公司 | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042853-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | CYP11B2, CYP11B1, CYP17A1 | TSHR 4726/4885TP53 4403/4885TDP1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.